Monday's top analyst upgrades and downgrades included AbbVie, Alibaba, Archer Daniels Midland, Best Buy, Intel, Nikola, Peloton Interactive, SAP, Under Armour and Wynn Resorts.
Catabasis Pharmaceuticalswas absolutely devastated on Tuesday after the company announced top-line results from its late-stage study in muscular dystrophy.
Thursday's top analyst upgrades and downgrades included Alibaba, BlackRock, Devon Energy, Domino's Pizza, DraftKings, Duke Energy, Enphase Energy, Snowflake, Valero Energy and Zillow.
Catabasis Pharma shares jumped early on Tuesday after the firm announced that it had completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment...
Cronos shares popped on Wednesday after Merrill Lynch released a very positive report. This is not something that happens every day, but the brokerage firm issued a double upgrade with very...
Catabasis shares jumped on Thursday after the company provided an update from its late-stage trial for edasalonexent in Duchenne muscular dystrophy.
Boring Company, owned by Elon Musk, will not complete one of its transportation tunnels. According to MarketWatch: Elon Musk’s Boring Co. has dropped plans for a test tunnel on the west side of...
Catabasis Pharmaceuticals shares made a handy gain on Tuesday after the company announced early stage data from its Duchenne muscular dystrophy study.
Catabasis Pharmaceuticals saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy study with edasalonexent.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altria, Apple, General Motors, Procter & Gamble and Walmart.
Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.
Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a late-breaking session at the World Muscle Society...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s...
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altria, Apple, Discovery, DowDuPont, JPMorgan, Red Hat and T-Mobile.